| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
|
Blood
|
2011
|
8.26
|
|
2
|
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
|
Blood
|
2010
|
7.25
|
|
3
|
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
|
Blood
|
2010
|
5.95
|
|
4
|
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
|
Blood
|
2003
|
3.16
|
|
5
|
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
|
J Clin Oncol
|
2009
|
3.13
|
|
6
|
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
|
J Immunother
|
2006
|
2.86
|
|
7
|
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
|
Blood
|
2012
|
2.52
|
|
8
|
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
|
Blood
|
2011
|
2.28
|
|
9
|
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
|
J Clin Oncol
|
2005
|
2.16
|
|
10
|
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
|
J Clin Oncol
|
2012
|
2.15
|
|
11
|
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications.
|
Haematologica
|
2011
|
1.89
|
|
12
|
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.
|
J Clin Oncol
|
2009
|
1.86
|
|
13
|
Minimal residual disease: what are the minimum requirements?
|
J Clin Oncol
|
2014
|
1.76
|
|
14
|
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology.
|
Blood
|
2004
|
1.65
|
|
15
|
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
|
Clin Cancer Res
|
2010
|
1.64
|
|
16
|
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
|
Nat Med
|
2005
|
1.63
|
|
17
|
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.
|
Blood
|
2009
|
1.59
|
|
18
|
Evidence of canonical somatic hypermutation in hairy cell leukemia.
|
Blood
|
2011
|
1.55
|
|
19
|
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
|
Clin Cancer Res
|
2009
|
1.53
|
|
20
|
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy.
|
Clin Cancer Res
|
2010
|
1.44
|
|
21
|
PRAME expression in hairy cell leukemia.
|
Leuk Res
|
2008
|
1.41
|
|
22
|
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
|
Blood
|
2010
|
1.30
|
|
23
|
Variables affecting the quantitation of CD22 in neoplastic B cells.
|
Cytometry B Clin Cytom
|
2010
|
1.21
|
|
24
|
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
|
Br J Haematol
|
2010
|
1.19
|
|
25
|
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.
|
Am J Hematol
|
2014
|
1.15
|
|
26
|
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene.
|
Am J Clin Pathol
|
2003
|
1.09
|
|
27
|
Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow.
|
Cytometry B Clin Cytom
|
2005
|
1.08
|
|
28
|
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
|
Leuk Lymphoma
|
2013
|
1.06
|
|
29
|
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
|
Blood
|
2013
|
1.06
|
|
30
|
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins.
|
Blood
|
2007
|
1.03
|
|
31
|
Flow cytometric immunophenotyping of cerebrospinal fluid.
|
Curr Protoc Cytom
|
2008
|
1.03
|
|
32
|
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
|
Br J Haematol
|
2007
|
1.01
|
|
33
|
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders.
|
Am J Clin Pathol
|
2011
|
0.98
|
|
34
|
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria.
|
Leuk Res
|
2013
|
0.97
|
|
35
|
Flow cytometry immunophenotyping of hematolymphoid neoplasia.
|
Methods Mol Biol
|
2011
|
0.96
|
|
36
|
Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma.
|
Semin Hematol
|
2011
|
0.91
|
|
37
|
Adult T-cell leukemia/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study.
|
Cancer
|
2002
|
0.91
|
|
38
|
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
|
Blood
|
2012
|
0.90
|
|
39
|
Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors.
|
Blood
|
2004
|
0.90
|
|
40
|
Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
|
Br J Haematol
|
2009
|
0.90
|
|
41
|
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.
|
Clin Cancer Res
|
2006
|
0.89
|
|
42
|
Soluble CD22 as a tumor marker for hairy cell leukemia.
|
Blood
|
2008
|
0.88
|
|
43
|
Large granular lymphocytic proliferation-associated cyclic thrombocytopenia.
|
Am J Hematol
|
2005
|
0.86
|
|
44
|
Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy.
|
Am J Clin Pathol
|
2011
|
0.85
|
|
45
|
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious.
|
Cancer
|
2006
|
0.84
|
|
46
|
Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2011
|
0.84
|
|
47
|
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
|
Leuk Lymphoma
|
2011
|
0.83
|
|
48
|
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
|
Exp Hematol
|
2013
|
0.82
|
|
49
|
Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy.
|
Cancer Immunol Immunother
|
2005
|
0.82
|
|
50
|
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.
|
Clin Cancer Res
|
2013
|
0.81
|
|
51
|
Variables in the quantification of CD4 in normals and hairy cell leukemia patients.
|
Cytometry B Clin Cytom
|
2011
|
0.81
|
|
52
|
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
|
Clin Cancer Res
|
2013
|
0.81
|
|
53
|
B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred.
|
Br J Haematol
|
2007
|
0.80
|
|
54
|
25-Gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma.
|
Br J Ophthalmol
|
2010
|
0.80
|
|
55
|
TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation.
|
Cancer Lett
|
2008
|
0.79
|
|
56
|
Visual inspection versus quantitative flow cytometry to detect aberrant CD2 expression in malignant T cells.
|
Cytometry B Clin Cytom
|
2010
|
0.79
|
|
57
|
Flow cytometric immunophenotyping: emerging as an important diagnostic tool in the evaluation of cytopenic patients.
|
Leuk Res
|
2009
|
0.79
|
|
58
|
Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
|
Cytometry B Clin Cytom
|
2009
|
0.79
|
|
59
|
Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.
|
Am J Clin Pathol
|
2010
|
0.78
|
|
60
|
Response of hairy cell leukemia to bendamustine.
|
Leuk Lymphoma
|
2011
|
0.78
|
|
61
|
Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia.
|
Cytometry B Clin Cytom
|
2008
|
0.78
|
|
62
|
Flow cytometric immunophenotypic assessment of T-cell clonality by vβ repertoire analysis in fine-needle aspirates and cerebrospinal fluid.
|
Am J Clin Pathol
|
2012
|
0.78
|
|
63
|
Immunoglobulin light chain repertoire in hairy cell leukemia.
|
Leuk Res
|
2007
|
0.78
|
|
64
|
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
|
Am J Hematol
|
2012
|
0.77
|
|
65
|
CD2 is expressed by a subpopulation of normal B cells and is frequently present in mature B-cell neoplasms.
|
Cytometry
|
2002
|
0.77
|
|
66
|
Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia.
|
Am J Clin Pathol
|
2013
|
0.77
|
|
67
|
Albumin enhanced morphometric image analysis in CLL.
|
Cytometry B Clin Cytom
|
2004
|
0.77
|
|
68
|
Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome.
|
Blood
|
2013
|
0.77
|
|
69
|
T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia.
|
Cytometry B Clin Cytom
|
2005
|
0.77
|
|
70
|
Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation.
|
Oncogene
|
2004
|
0.77
|
|
71
|
Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
72
|
Flow cytometry increases the sensitivity of detection of leukemia and lymphoma cells in bronchoalveolar lavage specimens.
|
Cytometry B Clin Cytom
|
2012
|
0.75
|
|
73
|
Persistent non-neoplastic gammadelta-T cells in cerebrospinal fluid of a patient with hepatosplenic (gammadelta) T cell lymphoma: a case report with 6 years of flow cytometry follow-up.
|
Int J Clin Exp Pathol
|
2009
|
0.75
|
|
74
|
Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review.
|
Clin Lymphoma
|
2002
|
0.75
|
|
75
|
Clinical quantitative flow cytometry: "Identifying the optimal methods for clinical quantitative flow cytometry".
|
Cytometry B Clin Cytom
|
2003
|
0.75
|
|
76
|
Case study interpretation--Portland: Case 1. Hairy cell leukemia with CLL-like monoclonal B lymphocytosis.
|
Cytometry B Clin Cytom
|
2012
|
0.75
|
|
77
|
Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method.
|
Leuk Lymphoma
|
2014
|
0.75
|